- Home
- RLMD vs OCGN Comparison
RLMD vs OCGN Comparison
Compare RLMD & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- OCGN
- Stock Information
- Founded
- RLMD 2004
- OCGN 2013
- Country
- RLMD United States
- OCGN United States
- Employees
- RLMD N/A
- OCGN N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLMD Health Care
- OCGN Health Care
- Exchange
- RLMD Nasdaq
- OCGN Nasdaq
- Market Cap
- RLMD 289.7M
- OCGN 321.7M
- IPO Year
- RLMD N/A
- OCGN N/A
- Fundamental
- Price
- RLMD $4.22
- OCGN $1.20
- Analyst Decision
- RLMD Buy
- OCGN Strong Buy
- Analyst Count
- RLMD 2
- OCGN 2
- Target Price
- RLMD $5.50
- OCGN $7.00
- AVG Volume (30 Days)
- RLMD 2.1M
- OCGN 3.2M
- Earning Date
- RLMD 11-13-2025
- OCGN 11-05-2025
- Dividend Yield
- RLMD N/A
- OCGN N/A
- EPS Growth
- RLMD N/A
- OCGN N/A
- EPS
- RLMD N/A
- OCGN N/A
- Revenue
- RLMD N/A
- OCGN $5,370,000.00
- Revenue This Year
- RLMD N/A
- OCGN N/A
- Revenue Next Year
- RLMD N/A
- OCGN N/A
- P/E Ratio
- RLMD N/A
- OCGN N/A
- Revenue Growth
- RLMD N/A
- OCGN 14.26
- 52 Week Low
- RLMD $0.24
- OCGN $0.52
- 52 Week High
- RLMD $5.12
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- RLMD 72.46
- OCGN 35.33
- Support Level
- RLMD $3.81
- OCGN $1.09
- Resistance Level
- RLMD $5.12
- OCGN $1.22
- Average True Range (ATR)
- RLMD 0.55
- OCGN 0.08
- MACD
- RLMD 0.05
- OCGN -0.01
- Stochastic Oscillator
- RLMD 64.44
- OCGN 26.87
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").